Long-circulating targeted nanoparticles for cancer therapy

Current Nanoscience

Volumn 6, Issue 4, 2010, Pages 347-354

  Liu, Yang ^a   Sun, Jin ^a   Han, Jihong ^b   He, Zhonggui ^a  

^a School of Pharmacy   (China)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

Cancer therapy; Long circulating nanoparticles; Nanoparticles; Targeted drug delivery

Indexed keywords

ANTINEOPLASTIC DRUGS; CANCER THERAPEUTICS; CANCER THERAPY; CELL INTERNALIZATION; CYTOTOXIC; DRUG DELIVERY SYSTEM; HYDROPHILIC POLYMERS; INTRAVENOUS ADMINISTRATION; LONG-CIRCULATING NANOPARTICLES; MULTIDRUG RESISTANCE; NANOPARTICLE SURFACE; POLYMERIC MICELLE; POLYMERIC NANOPARTICLES; SIDE EFFECT; SITE-SPECIFICITY; TARGET SITES; TARGETED DRUG DELIVERY; TARGETED NANOPARTICLE; TUMOR CELLS; TUMOR TARGETING;

DENDRIMERS; DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; ENZYME INHIBITION; LIPOSOMES; ONCOLOGY; PHOSPHOLIPIDS; TUMORS;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; AP 5280; AP 5346; CARBON NANOTUBE; CT 2106; DAUNORUBICIN; DE 310; DENDRIMER; DOXORUBICIN; FCE 28068; FCE 28069; IT 101; LIPOSOME; MACROGOL; NANOPARTICLE; NC 6004; NK 012; NK 105; NK 911; ONCOSPAR; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGAMOTECAN; PEGINTERFERON ALPHA2A; PNU 166148; PNU 166945; POLYAMIDOAMINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SILICON DIOXIDE; SP 1049C; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; INTRON; KAPOSI SARCOMA; LEUKEMIA; LYMPHOMA; MICELLE; MONOCYTE; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 79951711627     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/157341310791658991     Document Type: Article

References (87)

1. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers.Nat. Rev. Drug Discov., 2005, 4(2), 145-160.
2. Veronese, F.M.; Pasut, G. PEGylation, successful approach to drug delivery.Drug Discov. Today, 2005, 10(21), 1451-1458.
3. Liu, Z.; Jiao, Y.; Wang, Y.; Zhou, C.; Zhang, Z. Polysaccharides-basednanoparticles as drug delivery systems. Adv. Drug Deliv. Rev., 2008, 60(15),1650-1662.
4. Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemesfor nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008,60(15), 1615-1626.
5. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems forcancer therapy. Adv. Drug Deliv. Rev., 2004, 56(11), 1649-1659.
6. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment.Urol. Oncol., 2008, 26(1), 57-64.
7. Kukowska-Latallo, J.F.; Candido, K.A.; Cao, Z.; Nigavekar, S.S.; Majoros, I.J.; Thomas, T.P.; Balogh, L.P.; Khan, M.K.; Baker, J.R. Jr. Nanoparticletargeting of anticancer drug improves therapeutic response in animal modelof human epithelial cancer. Cancer Res., 2005, 65(12), 5317-5324.
8. Romberg, B.; Hennink, W.E.; Storm, G. Sheddable coatings for longcirculatingnanoparticles. Pharm. Res., 2008, 25(1), 55-71.
9. You, H.B. Drug targeting and tumor heterogeneity. J. Control. Release,2009, 133(1), 2-3.
10. Zhang, Y.; Zhang, J. Surface modification of monodisperse magnetitenanoparticles for improved intracellular uptake to breast cancer cells. J. ColloidInterface Sci., 2005, 283(2), 352-357.
11. Gref, R.; Lück, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Müller, R.H. 'Stealth' corona-core nanoparticles surface modifiedby polyethylene glycol (PEG): influences of the corona (PEG chain lengthand surface density) and of the core composition on phagocytic uptake andplasma protein adsorption. Colloids Surf. B Biointerfaces, 2000, 18(3-4),301-313.
12. Cheng, J.; Teply, BA.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F.X.; Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Formulationof functionalized PLGA-PEG nanoparticles for in vivo targeteddrug delivery. Biomaterials, 2007, 28(5), 869-876.
13. Moghimi, S.M.; Porter, C.J.; Muir, I.S.; Illum, L.; Davis, S.S. Nonphagocyticuptake of intravenously injected microspheres in rat spleen-influence ofparticle-size and hydrophilic coating. Biochem. Biophys. Res. Commun.,1991, 177(2), 861-866.
14. Stolnik, S.; Heald, C.R.; Neal, J.; Garnett, M.C.; Davis, S.S.; Illum, L.; Purkis, S.C.; Barlow, R.J.; Gellert, P.R. Polylactide-poly(ethylene glycol)micellar-like particles as potential drug carriers: production, colloidal propertiesand biological performance. J. Drug Target, 2001, 9(5), 361-378.
15. Porter, C.J.; Moghimi, S.M.; Illum, L.; Davis, S.S. The Polyoxyethylenepolyoxypropylene block copolymer poloxamer-407 selectively redirects intravenouslyinjected microspheres to sinusoidal endothelial cells of rabbitbone marrow. FEBS Lett., 1992, 305(1), 62-66.
16. Levchenko, T.S.; Rammohan, R.; Lukyanov, A.N.; Whiteman, K.R.; Torchilin, V.P. Liposome clearance in mice: the effect of a separate andcombined presence of surface charge and polymer coating. Int. J. Pharm.,2002, 240(1-2), 95-102.
17. Reddy, L.H.; Sharma, R.K.; Chuttani, K.; Mishra, A.K.; Murthy, R.R.Etoposide-incorporated tripalmitin nanoparticles with different surfacecharge: formulation, characterization, radiolabeling, and biodistribution studies.AAPS. J., 2004, 6(3), e23.
18. Sengupta, S.; Tyagi, P.; Velpandian, T.; Gupta, Y. K.; Gupta, S.K. Etoposideencapsulated in positively charged liposomes: pharmacokinetic studies inmice and formulation stability studies. Pharmacol. Res., 2000, 42(5), 459-464.
19. Yu, H.Y.; Lin, C.Y. Uptake of charged liposomes by the rat liver. J. Formos.Med. Assoc., 1997, 96(6), 409-413.
20. Hernández-Caselles, T.; Villalaín, J.; Gómez-Fernández, J.C. Influence ofliposome charge and composition on their interaction with human blood serumproteins. Mol. Cell. Biochem., 1993, 120(2), 119-126.
21. Krasnici, S.; Werner, A.; Eichhorn, M.E.; Schmitt-Sody, M.; Pahernikm, S.A.; Sauer, B.; Schulze, B.; Teifel, M.; Michaelis, U.; Naujoks, K.; Dellian, M. Effect of the surface charge of liposomes on their uptake by angiogenictumor vessels. Int. J. Cancer, 2003, 105(4), 561-567.
22. Lappalainen, K.; Miettinen, R.; Kellokoski, J.; Jaaskelainen, I.; Syrjanen, S.Intracellular distribution of oligonucleotides delivered by cationic liposomes:light and electron microscopic study. J. Histochem. Cytochem., 1997, 45(2),265-274.
23. McLean, J.W.; Fox, E.A.; Baluk, P.; Bolton, P.B.; Haskell, A.; Pearlman, R.; Thurston, G.; Umemoto, E.Y.; McDonald, D.M. Organ-specific endothelialcell uptake of cationic liposome-DNA complexes in mice. Am. J. Physiol.,1997, 273(1 pt 2), H387-404.
24. Romberg, B.; Oussoren, C.; Snel, C. J.; Hennink,W.E.; Storm, G. Effect ofliposome characteristics and dose on the pharmacokinetics of liposomescoated with poly(amino acid)s. Pharm. Res., 2007, 24(12), 2394-2401.
25. Allen, T.M.; Cheng, W.W.; Hare, J.I.; Laginha, K.M. Pharmacokinetics andpharmacodynamics of lipidic nano-particles in cancer. Anticancer AgentsMed. Chem., 2006, 6(6), 513-523.
26. Hamidi, M.; Azadi, A.; Rafiei, P. Pharmacokinetic consequences of pegylation. Drug Deliv., 2006, 13(6), 399-409.
27. Owens, D.E.; Peppas, N.A. Opsonization, biodistribution,and pharmacokineticsof polymeric nanoparticles. Int. J. Pharm., 2006, 307(1), 93-102.
28. Pirollo, K.F.; Chang, E.H. Dose a targeting ligand influence nanoparticletumor localization or uptake? Trends Biotechnol., 2008, 26(10), 552-558.
29. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and targetspecificnanoparticles: Theory to practice. Pharmacol. Rev., 2001, 53(2),283-318.
30. Dams, E.T.; Oyen, W.J.; Boerman, O.C.; Storm, G.; Laverman, P.; Kok, P.J.; Buijs, W.C.; Bakker, H.; van der Meer, J.W.; Corstens, F.H. 99mTc-PEGliposomes for the scintigraphic detection of infection and inflammation:clinical evaluation. J. Nucl. Med., 2000b, 41, 622-630.
31. Szebeni, J.; Baranyi, L.; Savay, S.; Lutz, H.; Jelezarova, E.; Bunger, R.; Alving, C.R. The role of complement activation in hypersensitivity to Pegylatedliposomal doxorubicin (Doxil). J. Liposome. Res., 2000, 10, 467-481.
32. Passirani, C.; Barratt, G.; Devissaguet, J.P.; Labarre, D. Long-circulatingnanoparticles bearing heparin or dextran covalently bound to poly(MethylMethacrylate). Pharm. Res., 1998, 15(7), 1046-1050.
33. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles:critical issues in pharmacokinetics, opsonization and protein-bindingproperties. Prog. Lipid Res., 2003, 42(6), 463-478.
34. Tröster, S.D.; Müller, U.; Kreuter, J. Modification of the body distribution ofpoly(methyl methacrylate) nanoparticles in rats by coating with surfactant.Int. J. Pharm., 1990, 61, 85-100.
35. Chambers, E.; Mitragotri, S. Long circulating nanoparticles via adhesion onred blood cells: mechanism and extended circulation. Exp. Biol. Med.(Maywood), 2007, 232(7), 958-966.
36. Lü, J.M.; Wang, X.; Marin-Muller, C.; Wang, H.; Lin, P.H.; Yao, Q.; Chen,C. Current advances in research and clinical applications of PLGA-basednanotechnology. Expert. Rev. Mol. Diagn., 2009, 9(4), 325-341.
37. Saxena, V.; Sadoqi, M.; Shao, J. Polymeric nanoparticulate delivery systemfor indocyanine green: biodistribution in healthy mice. Int. J. Pharm., 2006,308(1-2), 200-204.
38. Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles for biologicaland pharmaceutical applications. Adv. Drug Deliv. Rev., 2003, 55(3),403-419.
39. Mosqueira, V.C.F.; Legrand, P.; Morgat, J.L.; Vert, M.; Mysiakine, E.; Gref, R.; Devissaguet, J.P.; Barratt, G. Biodistribution of long-circulating PEGgraftednanocapsules in mice: effects of PEG chain length and density.Pharm. Res., 2001, 18(10), 1411-1419.
40. Gref, R.; Domb, A.; Quellec, P.; Blunk, T.; Müller, R. H.; Verbavatz, J. M.; Langer, R. The controlled intravenous delivery of drugs using PEG-coatedsterically stabilized nanospheres. Adv. Drug Deliv. Rev., 1995, 16, 215-233.
41. Oja, C. D.; Semple, S.C.; Chonn, A.; Cullis, P. R. Influence of dose onliposome clearance: critical role of blood proteins. Bio-Chim. Biophys. Acta,1996, 1281(1), 31-37.
42. Sheng, Y.; Liu, C.; Yuan, Y.; Tao, X.; Yang, F.; Shan, X.; Zhou, H.; Xu, F. Long-circulating polymeric nanoparticles bearing a combinatorial coating ofPEG and water-soluble chitosan. Biomaterials., 2009, 30(12), 2340-2348.
43. Avgoustakis, K. Pegylated poly(lactide) and poly(lactide-co-glycolide)nanoparticles: preparation, properties and possible applications in drug delivery.Curr. Drug Deliv., 2004, 1(4), 321-333.
44. Béduneau, A.; Saulnier, P.; Anton, N.; Hindré, F.; Passirani, C.; Rajerison, H.; Noiret, N.; Benoit, J.P. Pegylated nanocapsules produced by an organicsolvent-free method: evaluation of their stealth properties. Pharm. Res.,2006, 23(9), 2190-2199.
45. Khalid, M.N.; Simard, P.; Hoarau, D.; Dragomir, A.; Leroux, J.C. Longcirculating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxelto solid tumors. Pharm. Res., 2006, 23(4), 752-758.
46. Yuan, F. Transvascular drug delivery in solid tumors. Semin. Radiat. Oncol.,1998, 8(3), 164-175.
47. Agarwal, A.; Saraf, S.; Asthana, A.; Gupta, U.; Gajbhiye, V.; Jain, N.K.Ligand based dendritic systems for tumor targeting. Int. J. Pharm., 2008,350(1-2), 3-13.
48. Kobayashi, T.; Ishida, T.; Okada, Y.; Ise, S.; Harashima, H.; Kiwada, H. Effect of transferrin receptor-targeted liposomal doxorubicin in Pglycoprotein-mediated drug resistant tumor cells. Int. J. Pharm., 2007,329(1-2), 94-102.
49. Chapman, A.P. PEGylated antibodies and antibody fragments for improvedtherapy: a review. Adv. Drug Deliv. Rev., 2002, 54(4), 531-545.
50. Hatakeyama, H.; Akita, H.; Ishida, E.; Hashimoto, K.; Kobayashi, H.; Aoki, T.; Yasuda, J.; Obata, K.; Kikuchi, H.; Ishida, T.; Kiwada, H.; Harashima, H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEGliposomes. Int. J. Pharm., 2007, 342, 194-200.
51. Kitamura, K.; Takahashi, T.; Yamaguchi, T.; Noguchi, A.; Noguchi, A.; Takashina, K.; Tsurumi, H.; Inagake, M.; Toyokuni, T.; Hakomori, S. Chemical engineering of the monoclonal antibody A7 by polyethylene glycolfor targeting cancer chemotherapy. Cancer Res., 1991, 51 (16), 4310-4315.
52. Lee, L.S.; Conover, C.; Shi, C.; Whitlow, M.; Filpula, D. Prolonged circulatinglives of single-chain Fv proteins conjugated with polyethylene glycol: acomparison of conjugation chemistries and compounds. Bioconjug. Chem.,1999, 10(6), 973-981.
53. van Dijk, M.N.; van de Winkel, J.G.J. Human antibodies as next generationtherapeutics. Curr. Opin. Chem. Biol., 2001, 5(4), 368-374.
54. Shmeeda, H.; Mak, L.; Tzemach, D.; Astrahan, P.; Tarshish, M.; Gabizon, A.Intracellular uptake and intracavitary targeting of folate-conjugatedliposomes in a mouse lymphoma model with up-regulated folate receptors.Mol. Cancer Ther., 2006, 5(4), 818-824.
55. Sudimack, J.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv.Drug Deliv. Rev., 2000, 41(2), 147-162.
56. Low, P.S.; Antony, A.C. Folate receptor-targeted drugs for cancer and inflammatorydiseases. Adv. Drug Deliv. Rev., 2004, 56(8), 1055-1058.
57. Gabizon, A.; Shmeeda, H.; Horowitz, A.T.; Zalipsky, S. Tumor cell targetingof liposome-entrapped drugs with phospholipid-anchored folic acid-PEGconjugates. Adv. Drug Deliv. Rev., 2004, 56(8), 1177-1192.
58. Lee, R.J.; Low, P.S. Delivery of liposomes into cultured KB cells via folatereceptor-mediated endocytosis. J. Biol. Chem., 1994, 269(5), 3198-3204.
59. Bhadra, D.; Bhadra, S.; Jain, S.; Jain, N.K. A PEGylated dendritic nanoparticulatecarrier of fluorouracil. Int. J. Pharm., 2003, 257, 111-124.
60. Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. Functionalized micellar systemsfor cancer targeted drug delivery. Pharm. Res., 2007, 24(6), 1029-1046.
61. Lee, E.S.; Gao, Z.; Bae, Y.H. Recent progress in tumor pH targetingnanotechnology. J. Control. Release, 2008, 132(3), 164-170.
62. Sahoo, S.K.; Labhasetwar, V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellulardrug retention. Mol. Pharm., 2005, 2(5), 373-383.
63. Barraud, L.; Merle, P.; Soma, E.; Lefrançois, L.; Guerret, S.; Chevallier, M.; Dubernet, C.; Couvreur, P.; Trépo, C.; Vitvitski, L. Increase of doxorubicinsensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinomacells in vitro and in vivo. J. Hepatol., 2005, 42(5), 736-743.
64. Sharmaa, P.; Gantaa, S.; Dennyb, W.A.; Garg, S. Formulation and pharmacokineticsof lipid nanoparticles of a chemically sensitive nitrogen mustardderivative: Chlorambucil. Int. J. Pharm., 2009, 367(1-2), 187-194.
65. Decuzzi, P.; Ferrari, M. Design maps for nanoparticles targeting the diseasedmicrovasculature. Biomaterials., 2008, 29(3), 377-384.
66. Davis, M.E.; Chen, Z.G.; Shin, D.M. Nanoparticle therapeutics: an emergingtreatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782.
67. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J.Pharm., 2002, 235(1-2), 179-192.
68. Chen, D.B.; Yang, T.; Lu, W.L.; Zhang, Q. In vitro and in vivo study of twotypes of long-circulating solid lipid nanoparticles containing paclitaxel.Chem. Pharm. Bull., 2001, 49(11), 1444-1447.
69. Karmali, P.P.; Kotamraju, V.R.; Kastantin, M.; Black, M.; Missirlis, D.; Tirrell, M.; Ruoslahti, E. Targeting of albumin-embedded paclitaxel nanoparticlesto tumors. Nanomedicine, 2009, 5(1), 73-82.
70. Pulkkinen, M.; Pikkarainen, J.; Wirth, T.; Tarvainen, T.; Haapa-aho, V.; Korhonen, H.; Seppälä, J.; Järvinen, K. Three-step tumor targeting of paclitaxelusing biotinylated PLA-PEG nanoparticles and avidin-biotin technology:Formulation development and in vitro anticancer activity. Eur. J.Pharm. Biopharm., 2008, 70(1), 66-74.
71. Minow, R.A.; Benjamin, R.S.; Gottlieb, J.A. Adriamycin (NSC-123127)cardiomyopathy: an overview with determination of risk factors. CancerChemother. Pharmacol., 1975, 6, 195-201.
72. Bally, M.B.; Nayar, R.; Masin, D.; Hope, M.J.; Cullis, P.R.; Mayer, L.D. Liposomes with entrapped doxorubicin exhibit extended blood residencetimes. Biochim. Biophys. Acta, 1990, 1023(1), 133-139.
73. Lee, R.J.; Low, P.S. Folate-mediated tumor cell targeting of liposomeentrappeddoxorubicin in vitro. Biochim. Biophys. Acta, 1995, 1233(2), 134-144.
74. Lasic, D.D. Doxorubicin in sterically stabilized liposomes. Nature, 1996,380(6574), 561-562.
75. Flenniken, M.L.; Liepold, L.O.; Crowley, B.E.; Willits, D.A.; Young, M.J.; Douglas, T. Selective attachment and release of a chemotherapeutic agentfrom the interior of a protein cage architecture. Chem. Commun. (Camb).,2005, 28(4), 447-479.
76. Sapra, P.; Moase, E.H.; Ma, J.; Allen, T.M. Improved therapeutic responsesin a xenograft model of human B lymphoma (Namalwa) for liposomal vincristineversus liposomal doxorubicin targeted via Anti-CD19 IgG2a orFab' fragments. Clin. Cancer Res., 2004, 10(3), 1100-1111.
77. Huang, R.S.; Duan, S.; Kistner, E.O.; Bleibel, W.K.; Delaney, S.M.; Fackenthal, D.L.; Das, S.; Dolan, M.E. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res., 2008, 68(9), 3161-3168.
78. Wojnowski, L.; Kulle, B.; Schirmer, M.; Schlüter, G.; Schmidt, A.; Rosenberger, A.; Vonhof, S.; Bickeböller, H.; Toliat, M.R.; Suk, E.K.; Tzvetkov, M.; Kruger, A.; Seifert, S.; Kloess, M.; Hahn, H.; Loeffler, M.; Nürnberg, P.; Pfreundschuh, M.; Trümper, L.; Brockmöller, J.; Hasenfuss, G. NAD(P)Hoxidase and multidrug resistance protein genetic polymorphisms are associatedwith doxorubicin-induced cardiotoxicity. Circulation, 2005, 112(24),3754-3762.
79. O'Brien, M.E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczak, P.; Ackland, S.P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacyin a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment ofmetastatic breast cancer. Ann. Oncol., 2004, 15(3), 440-449.
80. Working, P.K.; Newman, M.S.; Sullivan, T.; Yarrington, J. Reduction of thecardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in longcirculating,pegylated liposomes. J. Pharmacol. Exp. Ther., 1999, 289(2),1128-1133.
81. Richardson, D.S.; Kelsey, S.M.; Johnson, S.A.; Tighe, M.; Cavenagh, J.D.; Newland, A.C. Early evaluation of liposomal daunorubicin (DaunoXomer®,Nexstar) in the treatment of relapsed and refractory lymphoma. Invest. NewDrugs, 1997, 15(3), 247-253.
82. Chen, B.; Cheng, J.; Wu, Y.; Gao, F.; Xu, W.; Shen, H.; Ding, J.; Gao, C.; Sun, Q.; Sun, X.; Cheng, H.; Li, G.; Chen, W.; Chen, N.; Liu, L.; Li, X.; Wang, X. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticlecopolymerizating daunorubicin and 5-bromotetrandrine in xenograft nudemice.Int. J. Nanomed., 2009, 4(1), 73-78.
83. Chen, B.; Cheng, J.; Shen, M.; Gao, F.; Xu, W.; Shen, H.; Ding, J.; Gao, C.; Sun, Q.; Sun, X.; Cheng, H.; Li, G.; Chen, W.; Chen, N.; Liu, L.; Li, X.; Wang, X. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interactsynergistically to induce apoptosis by daunorubicin in leukemia cells. Int. J.Nanomed., 2009, 4(1), 65-71.
84. Chen, H.; Gao, J.; Lu, Y.; Kou, G.; Zhang, H.; Fan, L.; Sun, Z.; Guo, Y.; Zhong, Y. Preparation and characterization of PE38KDEL-loaded anti-HER2nanoparticles for targeted cancer therapy. J. Control. Release, 2008, 128(3),209-216.
85. Ferrara, N.; Hillan, K.J.; Novotny, W. Bevacizumab (Avastin), a humanizedanti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res.Commun., 2005, 333 (2), 328-335.
86. Tseng, C.L.; Wu, S.Y.; Wang, W.H.; Peng, C.L.; Lin, F.H.; Lin, C.C.; Young, T.H.; Shieh, M.J. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol deliveryin nude mice with lung cancer. Biomaterials, 2008, 29(20), 3014-3022.
87. Jain, A.; Jain, S.K. In vitro and cell uptake studies for targeting of ligandanchored nanoparticles for colon tumors. Eur. J. Pharm. Sci., 2008, 35(5),404-416.